F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
40 hedge funds and large institutions have $22.3M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 10 closing their positions.
2.05% less ownership
Funds ownership: 41.22% → 39.17% (-2.1%)
11% less capital invested
Capital invested by funds: $25M → $22.3M (-$2.69M)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
20% less funds holding
Funds holding: 50 → 40 (-10)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$410K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$318K |
| 3 |
JP Morgan Chase
New York
|
+$149K |
| 4 |
MAM
Morse Asset Management
Darien,
Connecticut
|
+$127K |
| 5 |
TA
Tiedemann Advisors
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$605K |
| 2 |
Millennium Management
New York
|
-$466K |
| 3 |
Goldman Sachs
New York
|
-$363K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$230K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$181K |
FSTX Hedge Fund Activity: Q3 2019 in Review
40 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2019, worth a combined $22.3M — down 11% from $25M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FSTX and 1 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 11 added.
The largest buyer was Hikari Power, adding an estimated $410K. The largest seller was Northern Trust, cutting an estimated $605K.
- 40 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2019, down from 50 in Q2 2019.
- Funds reported $22.3M of F-star Therapeutics, Inc. Common Stock stock for Q3 2019, down 11% quarter-over-quarter.
- 1 fund opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2019 and 10 closed out, a net change of -9 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2019 was Hikari Power, an estimated $410K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2019 was Northern Trust, an estimated $605K sold.
Based on aggregated 13F filings for Q3 2019.